Hevascol

Hevascol is a radiographic contrast agent whose active ingredient is ethyl esters of iodised fatty acids derived from poppyseed oil. It is supplied as a sterile solution for injection, with the exact concentration not publicly disclosed, and is marketed in the European Union as a prescription‑only product. The formulation is designed for intra‑arterial and intralymphatic administration during diagnostic imaging procedures and helps improve visualization of vascular and lymphatic structures.

Hevascol is employed as an iodinated contrast medium in several diagnostic imaging techniques that require high‑contrast visualization of blood vessels and lymphatic channels.

- Angiography procedures, including arterial, venous, and capillary assessments, to visualize vessel lumen and pathology. - Lymphography for detailed imaging of lymphatic vessels, nodes, and potential metastatic pathways. - Intra‑arterial imaging during interventional radiology to guide catheter placement, embolization, or stent deployment. - Contrast‑enhanced CT or fluoroscopic examinations where direct intra‑arterial injection provides superior contrast resolution compared with intravenous administration. - Pre‑operative vascular mapping to assist surgeons in planning procedures such as bypass grafting or aneurysm repair.

Adverse reactions to Hevascol are generally related to its iodine content and the physicochemical properties of the injectable solution.

Common: - Transient warmth or flushing at the injection site. - Mild nausea or vomiting. - Headache or dizziness. - Temporary increase in heart rate or mild hypertension. - Localized pain or discomfort at the injection site.

Serious: - Severe allergic or anaphylactoid reaction, including bronchospasm and hypotension. - Acute kidney injury, particularly in patients with pre‑existing renal impairment. - Cardiac arrhythmias or myocardial ischemia triggered by contrast exposure. - Pulmonary edema or acute respiratory distress syndrome (ARDS) following high‑volume administration.

Before using Hevascol, clinicians should evaluate patient history and clinical status to minimize the risk of adverse events.

- Assess renal function; avoid use in patients with severe renal insufficiency unless benefits outweigh risks. - Review history of iodine allergy, previous contrast reactions, or asthma. - Use the lowest effective volume and concentration for the intended imaging study. - Ensure adequate hydration before and after the procedure to support renal clearance. - Monitor vital signs and oxygen saturation during and after injection, especially in high‑risk patients. - Consider alternative imaging modalities for pregnant or lactating women, as safety data are limited. - Verify correct intra‑arterial or intralymphatic catheter placement to prevent extravasation.

Hevascol may interact with other agents that affect renal function, hemodynamics, or hypersensitivity risk.

Avoid: - Concurrent use of nephrotoxic drugs such as aminoglycosides, amphotericin B, or high‑dose NSAIDs. - Administration of other iodinated contrast agents within a short interval, which can increase cumulative iodine load.

Use with caution: - Beta‑blockers or calcium channel blockers, which may mask contrast‑induced hypertension. - Diuretics, especially loop diuretics, that can alter fluid balance and renal clearance. - Antihistamines or corticosteroids, which may be required to manage mild allergic reactions but do not eliminate the risk of severe responses. - Radiopharmaceuticals or other imaging agents that could interfere with diagnostic interpretation.